Catalyst Pharmaceuticals Comments on Recent Decision by Health Canada to Re-issue an NOC for Ruzurgi®
Catalyst and its Canadian sublicensee,
Firdapse® is currently being evaluated in clinical trials for the treatment of MuSK-MG and has received Orphan Drug Designation from the FDA for myasthenia gravis.
Catalyst's Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including (i) whether any future legal challenge by Catalyst and KYE to the NOC recently granted for Ruzurgi® will be successful, (ii) whether commercialization of Firdapse® in
David Schull Russo Partners(212) 845-4271 email@example.com Company Contact Patrick J. McEnany Catalyst PharmaceuticalsChief Executive Officer (305) 420-3200 firstname.lastname@example.org
Source: Catalyst Pharmaceuticals, Inc.